Search

Objective: To compare the safety and efficacy of Kang'ai injection combined with chemotherapy and chemotherapy alone in the treatment of non-small cell lung cancer. Methods: The related control and randomized studies from 1966 to October 01, 2022, were retrieved in the following databases: China National Knowledge Infrastructure, Wanfang databases, Value In Paper, SinoMed, PubMed, Embase and Cochrane Library. A comprehensive literature search was conducted in 7 electronic databases identifying all the relevant randomized controlled trials. Cochrane handbook 5.2.3 was applied to evaluate the quality of included trials, and the RevMan 5.3 software was used to analyze data and assess the publication bias. Results: From the 16 studies reviewed, a total of 1,398 patients were included. Compared with docetaxel + cis-platinum chemotherapy alone, Kang'ai injection combined with docetaxel + cis-platinum chemotherapy showed significant effects in improving clinical response rate (RR: 1.40, 95% confidence interval (CI) (1.25, 1.58)), quality of life score (Karnofsky score) (RR: 1.53, 95% CI (1.32, 1.78)), traditional Chinese medicine syndrome (RR: 2.01, 95% CI (1.43, 2.83)) and safety (RR: 0.62, 95% CI (0.54, 0.71)), the differences were statistically significant. Conclusion: Kang'ai injection may increase the therapeutic effectiveness, improve the quality of life, and reduce the toxicity of chemotherapy in patients with non-small cell lung cancer. These results require confirmation by further rigorously designed randomized controlled trials (PROSPERO registration number: CRD42020176917). [ABSTRACT FROM AUTHOR]